Screening study of new thiazolidinone derivatives for anticonvulsant activity
DOI:
https://doi.org/10.14739/2310-1210.2020.6.218463Keywords:
antiepileptic drugs, epilepsy, thiazolidinone derivativesAbstract
The search for new antiepileptic drugs that would have greater margins of safety and fewer adverse effects is relevant. Thiazolidinone are a promising class for the development of new anticonvulsants.
Aim. To conduct a screening study of new thiazolidinone derivatives for anticonvulsant activity on a seizure model induced by pentylenetetrazole and maximal electroshock; to analyze the structure – activity relationship; to reveal a lead-compound and investigate its dose-dependent manner.
Materials and methods. Basic screening seizure models of pentylenetetrazol and maximal electroshock test were used in mice. The test original 9 thiazolidinone derivatives (100 mg/kg) and the reference drugs of sodium valproate (300 mg/kg), carbamazepine (40 mg/kg) were administered intragastrically 30 minutes before subcutaneous administration of pentylenetetrazol (90 mg/kg) or induction with maximal electroshock by giving a current with strength of 50 mA and frequency of 50 Hz for 0.2 s. In order to study the dose-dependent manner, the lead-compound was administered intragastrically in doses ranging from 25 mg/kg to 150 mg/kg.
Results. A total of 9 compounds were studied, of which 3 did not affect experimental convulsions, 2 showed proconvulsive activity, and 4 had an anticonvulsant effect. The lead-compound 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone was determined under laboratory code Les-6222, which exhibited the highest anticonvulsant properties. The “structure–anticonvulsant activity” relationship in a series of thiazolidinone derivatives was analyzed. The dose-dependent manner of 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone anticonvulsant effect was studied using 2 seizure models, and the most effective dose of 100 mg / kg was identified.
Conclusions. 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylamino)-4-thiazolidinone is a promising compound for in-depth studies on anticonvulsant and related pharmacological activities in order to develop new original anticonvulsants.
References
Espinosa-Jovel, C., Toledano, R., Aledo-Serrano, Á., García-Morales, I., & Gil-Nagel, A. (2018). Epidemiological profile of epilepsy in low income populations. Seizure, 56, 67-72. https://doi.org/10.1016/j.seizure.2018.02.002
Chen, Z., Brodie, M. J., Liew, D., & Kwan, P. (2018). Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. JAMA Neurology, 75(3), 279-286. https://doi.org/10.1001/jamaneurol.2017.3949
Bigelow, M. D., & Kouzani, A. Z. (2019). Neural stimulation systems for the control of refractory epilepsy: a review. Journal of NeuroEngineering and Rehabilitation, 16(1), Article 126. https://doi.org/10.1186/s12984-019-0605-x
Nikalje, A. P., Ansari, A., Bari, S., & Ugale, V. (2015). Synthesis, Biological Activity, and Docking Study of Novel Isatin Coupled Thiazolidin-4-one Derivatives as Anticonvulsants. Archiv Der Pharmazie, 348(6), 433-445. https://doi.org/10.1002/ardp.201500020
Jangam, S. S., Wankhede, S. B., & Chitlange, S. S. (2018). Molecular docking, synthesis and anticonvulsant activity of some novel 3-(2-substituted)-4-oxothiazolidine-3-yl)-2-phenylquinazoline-4(3H)-ones. Research on Chemical Intermediates, 45(2), 471-486. https://doi.org/10.1007/s11164-018-3612-9
Archana, & Saini, S. (2018). Synthesis and evaluation of some newerthiazolidinonyl substituted quinazolinones as potent anticonvulsant agents. International Journal of ChemTech Research, 11(11), 09-16. https://doi.org/10.20902/ijctr.2018.111102
Faizia, M., Jahania, R., Ebadib, S. A., Tabatabaic, S. A., Rezaeec, E., Lotfalieic, M., Aminid, M., & Almasiradb, A. (2017). Novel 4-thiazolidinone derivatives as agonists of benzodiazepine receptors: design, synthesis and pharmacological evaluation. EXCLI Journal, 16, 52-62. http://dx.doi.org/10.17179/excli2016-692
Kaur Manjal, S., Kaur, R., Bhatia, R., Kumar, K., Singh, V., Shankar, R., Kaur, R., & Rawal, R. K. (2017). Synthetic and medicinal perspective of thiazolidinones: A review. Bioorganic Chemistry, 75, 406-423. https://doi.org/10.1016/j.bioorg.2017.10.014
Pandey, A. K. (2019). Anticonvulsant activity of novel Schiff bases of thiadiazole derivatives. Bangladesh Journal of Pharmacology, 14(3), 127-128. https://doi.org/10.3329/bjp.v14i3.41543
Myronenko, S. I., Pinyazhko, О. R., & Lesyk, R. B. (2015). Skryninh spoluk z protysudomnoiu aktyvnistiu sered pokhidnykh 4-tiazolidynonu [Screening of compounds with anticonvulsant activity among 4-thiazolidinone derivatives]. Farmakolohiia ta likarska toksykolohiia, (4-5), 33-38. [in Ukrainian].
Mishchenko, M. V., Shtrygol, S. Yu., Lesyk, R. B., & Kaminskyi, D. V. (2019). Tiazolzamishcheni pokhidni 2,4-tiazolidyndionu, shcho vyiavliaiut antykonvulsantnu diiu [Thiazole-substituted 2,4-thiazolidinedione derivatives exhibiting anticonvulsant activity] (Ukraine. Patent No. 137726). Ukraina. Derzhavna sluzhba intelektualnoi vlasnosti Ukrainy. https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=262912 [in Ukrainian].
Myronenko, S. I., Kaminskyy, D. V., Nektegayev, I. O., Pinyazko, O. R., & Lesyk, R. B. (2012). Poshuk novykh antykonvulsantnykh ahentiv v riadu 4-tiazolidynoniv ta sporidnenykh heterotsyklichnykh system [Search of new anticonvulsant agents among 4-thiazolidinones and related heterocyclic systems]. Klinichna farmatsiia, farmakoterapiia ta medychna standartyzatsiia, (1-2), 124-131. [in Ukrainian].
Hock, F. J. (Ed.). (2016). Drug Discovery and Evaluation: Pharmacological Assays. Springer, Cham. https://doi.org/10.1007/978-3-319-05392-9
Mironov, A. N., Bunyatyan, N. D., Vasil'ev, A. N., Verstakova, O. L., Zhuravleva, M. V., Lepakhin, V. K., Korobov, N. V., Merkulov, V. A., Orekhov, S. N., Sakaeva, I. V., Uteshev, D. B., & Yavorskii, A. N. (Eds.). (2012). Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv. Chast' pervaya [Guidelines for conducting preclinical studies of drugs. Part one]. ZAO «Grif i K». [in Russian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
